相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A consensus on the diagnosis and treatment of acromegaly complications
S. Melmed et al.
PITUITARY (2013)
The changing face of acromegaly-advances in diagnosis and treatment
Antonio Ribeiro-Oliveira et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
Current management practices for acromegaly: an international survey
A. Giustina et al.
PITUITARY (2011)
Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
S. Petersenn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
A Consensus on Criteria for Cure of Acromegaly
A. Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide AutogelA® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Shlomo Melmed et al.
PITUITARY (2010)
Pituitary somatostatin receptor signaling
Anat Ben-Shlomo et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study
Annamaria Colao et al.
CLINICAL ENDOCRINOLOGY (2009)
Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Niels Moller et al.
ENDOCRINE REVIEWS (2009)
Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
I. M. Holdaway et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Pasireotide (SOM230): Development, mechanism of action and potential applications
Herbert A. Schmid
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Management of acromegaly: Is there a role for primary medical therapy?
Zachary M. Bush et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2008)
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
Moises Mercado et al.
CLINICAL ENDOCRINOLOGY (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
J van der Hoek et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Factors influencing mortality in acromegaly
IM Holdaway et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management
A Colao et al.
ENDOCRINE REVIEWS (2004)
Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment
Roberto Baldelli et al.
CLINICAL ENDOCRINOLOGY (2003)
Opportunities in somatostatin research: Biological, chemical and therapeutic aspects
G Weckbecker et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
分享论文
